Search - tctmd.com

Displaying 141 - 160 of 181

Sort: Relevancy | Date

Presentation TCT 2014

TCT 171: Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-term Oral Anticoagulation: A Pooled Analysis of Randomized Trials

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Matthew J. Price

September 15, 2014

Presentation TCT 2014

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

Presenter: Saibal Kar

September 15, 2014

Presentation TCT 2014

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

Presenter: Jai-Wun Park

September 15, 2014

Presentation TCT 2014

Watchman II: PROTECT-AF/PREVAIL Meta-analysis and Implications

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, David R. Holmes Jr.

September 15, 2014

Presentation TCT 2014

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

Presentation TCT 2014

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Vivek Y. Reddy

September 13, 2014

Presentation TCT 2014

Watchman Nightmare Case and Teaching Moment #1: A Perforation

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Maurice Buchbinder

September 13, 2014

Presentation TCT 2014

LAA Closure with the Watchman Device: A Perfect Case (Step-by-Step)

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Ramon Quesada

September 13, 2014

Presentation LAA 2014

Watchman: Registry Data from the “Real-World”

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Watchman: Randomized Trial Data in Anticoagulant Eligible Patients(from PROTECT AF to CAP to PREVAIL)

Presenter: David R. Holmes

July 19, 2014

Presentation LAA 2014

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Case 2: Watchman Implantation

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Do We Need More Data for Approving WATCHMAN?

Presenter: Jay N. Koneru

July 18, 2014

Presentation LAA 2014

The case of Watchman Approval

Presenter: Saibal Kar

July 18, 2014

Presentation LAA 2014

LAA Closure: The Device, Attribute and Basic Technique- The Watchman Device -

Presenter: Saibal Kar

July 17, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

Presentation TCT 2013

Anatomical Effect on Left Atrial After Transcatheter Left Atrial Appendage Devices: Watchman and Amplatzer Cardiac Plug in a Canine Model

Presenter: Dongming Hou

October 29, 2013

Presentation TCT 2013

Long Term Efficacy of Left Atrial Appendage Closure with WATCHMAN® Device

Presenter: Saibal Kar

October 29, 2013

Presentation TCT 2013

Are Novel LAA Closure Devices (Beyond Watchman) Needed in Germany?

Presenter: Gerald Werner

October 28, 2013

Presentation TCT 2013

Are Novel LAA Closure Devices (Beyond Watchman) Needed in the USA?

Presenter: Saibal Kar

October 28, 2013

Advertisement

TCT 171: Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-term Oral Anticoagulation: A Pooled Analysis of Randomized Trials

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

Watchman II: PROTECT-AF/PREVAIL Meta-analysis and Implications

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Watchman Nightmare Case and Teaching Moment #1: A Perforation

LAA Closure with the Watchman Device: A Perfect Case (Step-by-Step)

Watchman: Registry Data from the “Real-World”

Watchman: Randomized Trial Data in Anticoagulant Eligible Patients(from PROTECT AF to CAP to PREVAIL)

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Case 2: Watchman Implantation

Do We Need More Data for Approving WATCHMAN?

The case of Watchman Approval

LAA Closure: The Device, Attribute and Basic Technique- The Watchman Device -

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Anatomical Effect on Left Atrial After Transcatheter Left Atrial Appendage Devices: Watchman and Amplatzer Cardiac Plug in a Canine Model

Long Term Efficacy of Left Atrial Appendage Closure with WATCHMAN® Device

Are Novel LAA Closure Devices (Beyond Watchman) Needed in Germany?

Are Novel LAA Closure Devices (Beyond Watchman) Needed in the USA?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content